Aktis Oncology, a US-based clinical stage biotechnology company, announced on Tuesday that it has named Akos Czibere, MD, PhD, as its new chief medical officer.

Czibere has around 20 years of experience in drug development for hematologic and solid tumour cancers. He has served as vice president and therapeutic area head of Haematology-Oncology at Pfizer Inc. and vice president, Clinical Development at Merrimack Pharmaceuticals. Pankaj Bhargava, MD, who served as interim chief medical officer in connection with his entrepreneur partner role at MPM BioImpact, will transition to Aktis' Scientific Advisory Board (SAB).

Matthew Roden, PhD, Aktis president and chief executive officer, said: "Akos' broad experience and deep expertise in oncology drug development and regulatory affairs further strengthens our capabilities to deliver on the significant patient impact potential of our first-in-class Nectin-4-targeted miniprotein radioconjugate, as well as the multiple programs to follow. We thank Pankaj for his contributions to Aktis and look forward to his continued impact as a member of our SAB."